A Comparison of Long-acting Injectable Medications for Schizophrenia (ACLAIMS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01136772|
Recruitment Status : Completed
First Posted : June 3, 2010
Results First Posted : April 24, 2015
Last Update Posted : October 21, 2016
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Schizoaffective Disorder||Drug: haloperidol decanoate Drug: paliperidone palmitate||Phase 4|
The purpose of this comparative effectiveness research study is to learn more about different medications called antipsychotics that are used to treat schizophrenia or schizoaffective disorder. Specifically, we are looking at long-acting medications that are given by injection every month, instead of being taken by mouth every day. In this multi-site study, we are comparing the risk and benefits of two FDA-approved long-acting injectable medications (paliperidone palmitate and haloperidol decanoate). Study participants with schizophrenia or schizoaffective disorder are expected to benefit from the improved medication schedule.
This study aims to enroll 360 individuals with schizophrenia or schizoaffective disorder for whom treatment with a long-acting injectable antipsychotic medication is likely to be helpful. Study participants will be randomly assigned to treatment with either paliperidone palmitate and haloperidol decanoate for up to 24 months. Participants will have an equal chance of being assigned to each medication, however participants will not know which medication they are taking.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||311 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Comparison of Long-Acting Injectable Medications for Schizophrenia|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2016|
Experimental: Paliperidone palmitate
Intramuscular injections of paliperidone palmitate 39-234 mg every month
Drug: paliperidone palmitate
Paliperidone palmitate injections, 39 mg - 234 mg once a month
Other Name: Invega Sustenna
Active Comparator: Haloperidol decanoate
Intramuscular injections of haloperidol decanoate 25-200 mg every month
Drug: haloperidol decanoate
haloperidol decanoate injections, 25-200 mg once a month
Other Name: Haldol
- Efficacy Failure [ Time Frame: 24 months ]Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication.
- Changes in Psychiatric Symptoms [ Time Frame: Baseline to 6 months ]The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01136772
|Principal Investigator:||Scott Stroup, MD, MPH||Columbia University|
|Principal Investigator:||Joseph P McEvoy, MD||Duke University|